มอลตา - อังกฤษ - Malta Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents

มอลตา - อังกฤษ - Malta Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents

มอลตา - อังกฤษ - Malta Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 37.5 mg - antineoplastic agents

มอลตา - อังกฤษ - Malta Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 50 mg - antineoplastic agents

สหภาพยุโรป - อังกฤษ - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastic agents - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance.metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults.pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

dr.reddys laboratories inc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summarybased on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to

แคนาดา - อังกฤษ - Health Canada

teva canada limited - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg

แคนาดา - อังกฤษ - Health Canada

teva canada limited - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg

แคนาดา - อังกฤษ - Health Canada

teva canada limited - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg

มอลตา - อังกฤษ - Malta Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents